In 2013, the Ministry of Health, Labour, and Welfare issued a notiˆcation regarding drugs that in‰uence driving. Afterward, a questionnaire survey of these drugs was conducted involving health insurance pharmacies in Tokyo and Shiga Prefectures. As a result, 503 (Tokyo) and 116 (Shiga) pharmacies provided completed questionnaires. The notiˆ-cation was su‹ciently and slightly recognized by 20％ and 44％ of the surveyed pharmacies, respectively, and drugs with a driving-related warning were recognized by 31％ of the pharmacies. In addition, 23％ of the pharmacies reported that they always asked patients whether they drive. The in‰uence on driving of antianxiety drugs, hypnotics, antiepileptics, and smoking-cessation drugs was always explained to patients by 74％, 72％, 64％, and 40％ of the pharmacies, respectively. Concerning responses to the prescription of drugs in‰uencing driving, the proportion of surveyed pharmacies in Tokyo and Shiga Prefectures that directed patients not to drive was 71％ and 53％, respectively, and that directed patients to stop driving on developing any symptom was 32％ and 49％. Tokyo and Shiga Prefectures showed a signiˆcant diŠerence in the reason for not prohibiting driving; the proportion of pharmacies that regarded strict medication adherence as of major importance to treat patients' primary diseases was 22％ and 43％, respectively. This diŠerence might have been attributable to a high percentage of patients (80％) driving to pharmacies in Shiga Prefecture. To facilitate the prescription of drugs in‰uencing driving, it is recommended to design drug-speciˆc pharmaceutical education manuals that also give consideration to patients' QOL.